scholarly journals Antidiabetic and Antilipidemic Activity of Root Extracts of Salacia oblonga against Streptozotocin-Induced Diabetes in Wistar Rats

Processes ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 301 ◽  
Author(s):  
Kakara Gift Kumar Deepak ◽  
Surekha Challa ◽  
Ganta Suhasin ◽  
Neelapu Nagesewara Rao Reddy ◽  
Hosam O. Elansary ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Type Ii Diabetes Mellitus ◽  
Antidiabetic Activity ◽  
Root Extract ◽  
Dependent Manner ◽  
Type Ii ◽  
Root Extracts ◽  
Salacia Oblonga

Salacia oblonga is used to treat diabetes, hypocholesteremia, gonorrhea, rheumatism, asthma, inflammation, oxidative stress, etc. In the present study, the antidiabetic activity of S. oblonga methanolic root extracts collected from three geographical locations, viz., Eleshwaram (Andhra Pradesh), Thoothukudi (Tamil Nadu), and Karwar (Karnataka), was studied in vitro. Among the three extracts, S. oblonga root extracts from Eleshwaram showed maximum α-glucosidase and α-amylase inhibitory activities, indicating better antidiabetic activity. Acute toxicity studies of S. oblonga carried out in Albino Wistar rats showed no toxicity. Further, in vivo studies showed antidiabetic and antilipidemic activities in Albino Wistar rats with induced type II diabetes mellitus. Type II diabetes mellitus was induced in the experimental rats by intraperitoneal injection of nicotinamide and streptozotocin. The rats were orally fed different doses (ranging from 0 to 400 mg/kg body weight) of S. oblonga root extracts from Eleshwaram for 14 days. Blood glucose, lipid, bilirubin, and creatinine levels were analyzed on day 0, 7, and 14. The S. oblonga root extract from Eleshwaram decreased the glucose levels in a dose-dependent manner as well as the lipid, creatinine, and bilirubin levels in diabetic rats. Thus, the present study demonstrates antidiabetic and antilipidemic properties of S. oblonga root extracts.

scholarly journals Correction: Rubia tinctorum root extracts: chemical profile and management of type II diabetes mellitus

RSC Advances ◽  
2020 ◽  
Vol 10 (52) ◽  
pp. 31214-31214
Author(s):  
Enas E. Eltamany ◽  
Mohamed S. Nafie ◽  
Dina M. Khodeer ◽  
Aya H. H. El-Tanahy ◽  
Maged S. Abdel-Kader ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Chemical Profile ◽  
Root Extracts ◽  
Rubia Tinctorum

Correction for ‘Rubia tinctorum root extracts: chemical profile and management of type II diabetes mellitus’ by Enas E. Eltamany et al., RSC Adv., 2020, 10, 24159–24168, DOI: 10.1039/D0RA03442H.

scholarly journals A case study wistar rats by implementing Metformin on Clozapine

2018 ◽  
Vol 8 (1) ◽  
pp. 5-9
Author(s):  
Vinaya B ◽  
Akila CR ◽  
Dinesh Babu J ◽  
Sravan Kumar P
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Fasting Blood Glucose ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Metabolic Derangement ◽  
Group 2 ◽  
The Impact

The medical studies in beyond decade has reported that maximum 2nd-era antipsychotics (SGAs) can reason severe metabolic derangement, which significantly upsurges the danger for type II diabetes mellitus. Numerous retrospective studies have proven multiplied in serum triglyceride in sufferers handled with Clozapine. SGAs triggered metabolic syndrome is characterized via hypertension, weight gain, hyperglycaemia, hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is presently used to extravagance metabolic syndrome and type II diabetes mellitus. It is consequently essential to decide whether Metformin is effective in discussing Clozapine-brought on metabolic derangement like dyslipidaemia. To appraise the impact of Metformin in minimizing Clozapine caused metabolic irrationality like dyslipidaemia. Methodology: Wistar rats weighing a hundred and eighty-240g both intercourse had been divided into three corporations of 6 rats every. Group 1 attended as manipulate, Group 2 Preserved with Clozapine 25mg/kg frame weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg body weight for 30 days P.O. Group 2 and group three were preserved for 30 days. Lipid profile of institution 2 rats handled with Clozapine showed dyslipidaemia (TG 103.3±1.7mg/dl, Tc 113.7±1.6mg/dl). Whereas organization 3 rats treated with Clozapine 25mg + Metformin confirmed ordinary lipid levels (TG ninety four.7±1.7mg/dl, TC 102.Eight±0.Eight mg/dl) similar to institution 1(TG ninety three.0±2.6mg/dl, TC 103.7±1.5mg/dl). This study focuses a non-substantial increase in fasting blood glucose in SD rodents managed with clozapine that was in part checked by utilizing simultaneous organization of metformin. Rodents controlled clozapine affirmed the anticipated abatement in the statement of GLUT2, anyway simultaneous administration of metformin and clozapine for 30 days didn't show the anticipated standardization of the articulation degrees of GLUT2. This look at investigating the use of Metformin to forestall metabolic unsettling like dyslipidaemias in patients of schizophrenia managed with Clozapine.

scholarly journals ROLE OF METFORMIN ON CLOZAPINE INDUCED DYSLIPIDAEMIA IN WISTAR RATS

2018 ◽  
pp. 1-5
Author(s):  
Syed Shoib Md Hussaini ◽  
Akram A Naikwadi ◽  
Narsapur VU
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Type Ii Diabetes ◽  
Wistar Rats ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Metabolic Derangement ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Background: The clinical research in past decade has reported that most second-generation antipsychotics (SGAs) can cause serious metabolic derangement, which substantially increases the risk for type II diabetes mellitus. Several retrospective studies have shown increased in serum triglyceride in patients treated with Clozapine. SGAs induced metabolic syndrome is characterized by weight gain, hyperglycaemia, hypertension, hyperlipidaemia, glucose intolerance and insulin resistance. Metformin is currently used to treat metabolic syndrome and type II diabetes mellitus. It is therefore important to determine whether Metformin is efficacious in treating Clozapine-induced metabolic derangement like dyslipidaemia. Objectives: To evaluate the effect of Metformin in minimizing Clozapine induced metabolic derangement like dyslipidaemia. Methodology: Wistar rats weighing 180-240g either sex were divided into 3 groups of 6 rats each. Group 1 served as control, Group 2 Treated with Clozapine 25mg/kg body weight and Group 3 Treated with Clozapine 25mg + Metformin 100mg/kg body weight for 28 days P.O. Group 2 and group 3 were treated for 28 days. Biochemical investigations: Retro-orbital blood was collected for Lipid profile. Result: Lipid profile of group 2 rats treated with Clozapine showed dyslipidaemia (TG 103.3 ±1.7mg/dl, Tc 113.7 ±1.6mg/dl). Whereas group 3 rats treated with Clozapine 25mg + Metformin showed normal lipid levels (TG 94.7±1.7mg/dl, TC 102.8 ±0.8 mg/dl) comparable to group 1(TG 93.0 ±2.6mg/dl, TC 103.7 ±1.5mg/dl). Conclusion: This study exploring the use of Metformin to prevent metabolic derangement like dyslipidaemias in patients of schizophrenia treated with Clozapine. KEYWORDS: Clozapine; Metformin; Dyslipidaemia.

scholarly journals Formulation and Evaluation of Teneligliptin and Telmisartan Bilayer Tablets for the Treatment of Coexistent Type II Diabetes Mellitus and Hypertension

2019 ◽  
Vol 9 (5) ◽  
pp. 26-38
Author(s):  
Gaurav S. Lodha ◽  
Satyam Z Chemate
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Magnesium Stearate ◽  
Type Ii Diabetes Mellitus ◽  
Angle Of Repose ◽  
Antidiabetic Activity ◽  
Wet Granulation ◽  
Type Ii ◽  
Dose Frequency ◽  
Current Scenario

In the current scenario type two diabetes mellitus and hypertension have become prevalent in large number of population. But there are many patients which are suffering from Type II Diabetes Mellitus as well as hypertension. Such condition is called co-existent Type II Diabetes Mellitus and Hypertension. In the present work an attempt is made to treat co-existent type II Diabetes Mellitus and hypertension by formulating a Bilayer tablet of Teneligliptin and Telmisartan. Both drugs are sustained released to give a day long relief to the patients and to also reduce the dose frequency. Both the layers of the tablets were formulated by wet granulation method. The granules were tested for angle of repose, bulk density, tapped density, compressibility and Hausner’s ratio to check their efficacy. Eleven different types of formulations were made using various polymers and excipients with the drugs such as PVP K30, HPMC K4M, Starch, Crospovidone, Lactose, Mannitol, Talc and Magnesium Stearate. From these 11 formulations F6 showed better tablet characteristics and drug release rate than other formulations. Thus F6 is the best formulation in this study. Biological screening of the drugs combination of Teneligliptin and Telmisartan was also done to check the presence of antidiabetic activity of the combination which showed positive results. Keywords: - Teneligliptin, Telmisartan, Sustained, Bilayer. 

scholarly journals Nitric Oxide-Dependent Regulation of Cytokines Release in Type-II Diabetes Mellitus

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Maqsood M. Elahi ◽  
Bashir M. Matata
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Mononuclear Cells ◽  
Sandwich Elisa ◽  
Type Ii Diabetes Mellitus ◽  
No Production ◽  
Dependent Manner ◽  
Type Ii ◽  
Concentration Dependent Manner ◽  
Necrosis Factor

The mechanism of release of proinflammatory cytokines by blood granulocytes in diabetes is unknown. We investigated whether diabetes mellitus affects the production of cytokines by granulocytes (PMN) and mononuclear cells (PBMCs) and whether this is modulated by NO. Isolated PMN and PBMC from with or without type-II diabetes mellitus were incubated at 37°C for 6 h with S-nitroso-N-acetylpenicillamine (SNAP) at 0, 1, and 100 μM with or without lipopolysaccharides (LPS) stimulation (1 μg/mL). Supernatants were assayed for tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8) by sandwich ELISA. Significant increases in TNF-α and IL-8 were observed only in PMN from diabetic subjects with or without LPS stimulation and that exogenous NO inhibited further production of cytokines in a concentration-dependent manner. However, activity of PBMC when stimulated with LPS was greatly enhanced by diabetes, but not affected by NO production. Hence, suggesting that granulocytes activation and participation in diabetes related complications is modulated by NO bioavailability.

scholarly journals Rubia tinctorum root extracts: chemical profile and management of type II diabetes mellitus

RSC Advances ◽  
2020 ◽  
Vol 10 (41) ◽  
pp. 24159-24168
Author(s):  
Enas E. Eltamany ◽  
Mohamed S. Nafie ◽  
Dina M. Khodeer ◽  
Aya H. H. El-Tanahy ◽  
Maged S. Abdel-Kader ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Chemical Profile ◽  
Root Extracts ◽  
Rubia Tinctorum

The chemical and biological profiling of the root extracts of Rubia tinctorum was performed.

Sign in / Sign up

Export Citation Format

Share Document